

Snapshot COVID-19 data

Science, trial forecast, production and news analysis


December 8, 2020




Information for these slides is from public sources.
IFPMA is not involved in the collection of this data.

Daily infections per 10,000 people and testing capacity per capita

Infection Rate per 10,000

Continent ● Asia ● Africa ● Oceania ● North America ● South America ● Europe





Overview of treatments currently being used in a clinical setting

Type of treatment	Candidate/Intervention	Disease severity (Evidence in each indication)		
		Mild	Moderate	Severe/Critical
Anti-inflammatory or immunomodulator	Interferon Beta-1A			Equal to SOC
	Interferon Beta-1A (Nebulised)			Better than SOC
	Hydroxychloroquine	Rejected/Worse than SOC	Rejected/Worse than SOC	Rejected/Worse than SOC
	Remdesivir		Better than SOC	Better than SOC
Antiviral	Favipiravir	Better than SOC	Better than SOC	
	Lopinavir with Ritonavir			Rejected/Worse than SOC
	Camostat Mesylate			
	Umifenovir			
Steroid	Methylprednisolone		Better than SOC	Better than SOC
	Dexamethasone			Better than SOC
	Baricitinib (and Remdesivir)			Better than SOC
Antibody (anti-inflammatory)	Tocilizumab			Better than SOC
Other	Aviptadil			
Antithrombotic	Enoxaparin			
	Heparin			
Antibody (passive immunotherapy)	Regn-CoV2 (Regeneron/Roche)	Better than SOC	Better than SOC	
	Bamlanivimab (LyCov555)	Better than SOC	Better than SOC	
	Convalescent Plasma		Equal to SOC	Equal to SOC

Standard of care varies from trial to trial, but is considered to be the standard protocol of treatment of a patient at that stage of disease severity.

■ Better than SOC
 ■ Equal to SOC
■ Rejected/Worse than SOC
 ■ No/insufficient data


Total number of COVID-19 vaccine candidates

347



Total number of vaccines

Vaccines by vaccine type



Total doses committed in deals so far


10 932 180 000



Doses committed so far


Average number participants in phase III clinical trials

15 083




Average number of participants in phase III COVID-19 vaccine trials

Analysis of potential readouts of phase III vaccine trials




◆ ◆ ◆ ◆ Estimated interim analysis readout from first to fourth cohort
 ▲ Estimated primary endpoint readout
 ● Estimated time to 150 confirmed cases
 ● Estimated 2 month safety

Overview of second generation COVID-19 vaccines




Second generation COVID-19 vaccines	
Candidate	Phase III start
Sanofi/GSK vaccine	End of 2020
CureVac vaccine	Q4 2020
Themis/Merck candidate	End of 2020
Uni. of Queensland candidate	Dec 2020
ZyCoV-D (<i>Zydus Cadila</i>)	Dec 2020
Inactivated virus (<i>Chinese academy of MS</i>)	Nov/Dec 2020
Recombinant protein (<i>Zhifei</i>)	Dec 2020
VLP (<i>Medicago</i>)	Dec 2020

Expected vaccine production by end of 2021



Back to normal immunization forecasts

Timeline for countries/regions to reach herd immunity based on agreed vaccine supply deals



20% population immunised

Healthcare and high-risk population immunised

Herd immunity estimate, based on current supply deals, with domestic production supplied first

Copyright notice

All intellectual property rights in this publication and the information published herein are the exclusive property of Airfinity and may only be used under licence from Airfinity. Without limiting the foregoing, by accessing this publication you agree that you will not copy or reproduce or recirculate or distribute or use any part of its contents in any form or for any purpose whatsoever except under valid licence from Airfinity. Unauthorised distribution is strictly prohibited.

Disclaimer

The data and other information published herein are provided on an "as is basis". Airfinity makes no warranties, express or implied, as to the accuracy, adequacy, timeliness, or completeness of the data or fitness for any particular purpose. Airfinity shall not be liable for any loss, claims or damage arising from any party's reliance on the data and disclaim any and all liability relating to or arising out of use of the data to the full extent permissible by law.

For more information:

Rasmus Bech Hansen, CEO
rasmus@airfinity.com